Investment analysts at B. Riley increased their Q1 2025 earnings estimates for shares of Eton Pharmaceuticals in a research ...
Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Eton Pharmaceuticals in a report ...
N-acetylglutamate synthetase deficiency; OTC, ornithine transcarbamylase deficiency; PCD, pyruvate carboxylase deficiency; PA, propionic acidemia; THAN, transient hyperammonemia of the newborn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results